Skip to main content
Equibles

EPRX · Eupraxia Pharmaceuticals Inc. · Metrics

Track EPRX — free

Use EPRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$8.11 -0.14 (-1.70%)
Rebalance outlook locked
Market Cap
$545.11M
Shares
66.07M

EPRX metrics

39 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$8.25
Market cap
$545.11M

Price action

20 metrics
Price change (1W)
+25.8%
Price change (30D)
+26.1%
Price change (3M)
+41.2%
Price change (6M)
+5.1%
Price change (YTD)
+11.3%
Price change (1Y)
+56.7%
Trailing year
Price change (5Y)
—
52-week high
$9.07
52-week low
$5.27
Change from 52-week high
-7.4%
Change from 52-week low
+59.4%
Annualized volatility
65.9%
Annualized volatility (3M)
69.3%
Beta
1.6
RSI (14D)
69.3
Price vs SMA 50
+25.8%
Price vs SMA 200
+17.8%
Avg volume (3M)
428,293
Relative volume
8.2
Average dollar volume
$2.91M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
66.07M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
6.8
reciprocal yield 14.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.58

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+17.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-47.0%
Return on assets
-44.8%
Debt / equity
—
Current ratio
15.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
15.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$80.56M
Total assets
$86.15M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
68
13F filer change QoQ
+13
Institutional ownership
37.6%

Short interest

3 metrics
Short interest
9.6%
Latest settlement · 28.8 days to cover
Days to cover
28.8d
Short-squeeze score
100 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1581178 CUSIP 29842P105 13F (30d) 63 filings 61 filers Visit website Investor relations